Despite the current challenges to the ACA, the biopharmaceutical industry should engage proactively with lawmakers as Medicare and Medicaid face major reforms in the coming years, health policy experts urge at PhRMA’s annual meeting.

Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.

Bayer and Novartis are among a number of companies pushing to ensure a broad interpretation of exemption for orphan drugs from the annual market-based fees that drug firms newly owe under the Affordable Care Act.